For the year ending 2025-12-31, CCCC has $359,075K in assets. $102,488K in debts. $74,603K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 74,603 | |||
| Marketable securities, current | 173,934 | |||
| Accounts receivable | 2,401 | |||
| Prepaid expenses and other current assets | 7,172 | |||
| Total current assets | 258,110 | |||
| Marketable securities, non-current | 48,563 | |||
| Property and equipment, net | 4,744 | |||
| Right-of-use asset | 40,532 | |||
| Restricted cash | 3,443 | |||
| Other assets | 3,683 | |||
| Total assets | 359,075 | |||
| Accounts payable | 858 | |||
| Accrued expenses and other current liabilities | 13,314 | |||
| Deferred revenue, current | 12,493 | |||
| Operating lease liability, current | 6,367 | |||
| Total current liabilities | 33,032 | |||
| Deferred revenue, net of current | 15,841 | |||
| Operating lease liability, net of current | 53,615 | |||
| Total liabilities | 102,488 | |||
| Common stock, par value of 0.0001 per share 300,000,000 and 150,000,000 shares authorized as of december 31, 2025 and december 31, 2024, and 96,914,418 and 70,625,899 shares issued and outstanding as of december31, 2025 and 2024, respectively | 9 | |||
| Additional paid-in capital | 995,221 | |||
| Accumulated other comprehensive income | 50 | |||
| Accumulated deficit | -738,693 | |||
| Total stockholders equity | 256,587 | |||
| Total liabilities and stockholders equity | 359,075 | |||
C4 Therapeutics, Inc. (CCCC)
C4 Therapeutics, Inc. (CCCC)